EVGN
EVGN
NASDAQ · Biotechnology

Evogene Ltd

$0.43
+0.04 (+10.93%)
As of Jun 29, 10:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
7.85M
Net Income
-13,019,538
Gross Margin
-120.6%
Profit Margin
-800.8%
Rev Growth
+30.5%
D/E Ratio
0.95
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -120.6% -120.6% 51.3% 51.3%
Operating Margin -745.5% -671.0% 25.9% 22.8%
Profit Margin -800.8% -760.7% 25.9% 19.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 7.85M 6.01M 3.80M 4.24M
Gross Profit -9,465,006 -7,250,655 1.95M 2.18M
Operating Income -58,529,006 -40,352,463 984.3K 966.3K
Net Income -13,019,538 -8,976,240 985.2K 805.1K
Gross Margin -120.6% -120.6% 51.3% 51.3%
Operating Margin -745.5% -671.0% 25.9% 22.8%
Profit Margin -800.8% -760.7% 25.9% 19.0%
Rev Growth +30.5% +30.5% +24.5% -6.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.15M 1.15M 3.82M 3.96M
Total Equity 1.20M 1.20M 3.81M 3.70M
D/E Ratio 0.95 0.95 1.00 1.07
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -19,821,692 -14,425,162 1.34M 1.32M
Free Cash Flow 1.13M 1.05M